Enliven Therapeutics' (ELVN) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• Enliven Therapeutics (ELVN) has had its "sell (D-)" rating reaffirmed by Weiss Ratings, indicating concerns about its stock performance.
• HC Wainwright upgraded its price target for the stock from $40.00 to $48.00, and the company currently holds a consensus rating of "Moderate Buy" with an average target price of $41.20.
• Significant insider selling has occurred, with Joseph P. Lyssikatos and Anish Patel selling shares recently, leading to a 1.35% and 2.35% decrease in their respective ownership stakes.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by investment analysts at Weiss Ratings in a research note issued on Friday,Weiss Ratings reports.

Separately, HC Wainwright upped their price objective on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $41.20.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock opened at $20.61 on Friday. Enliven Therapeutics has a 52-week low of $13.30 and a 52-week high of $29.78. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -10.31 and a beta of 0.85. The company has a fifty day moving average of $20.16 and a 200-day moving average of $19.68.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. On average, equities research analysts forecast that Enliven Therapeutics will post -1.95 earnings per share for the current fiscal year.

Insider Activity

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 12,500 shares of the company's stock in a transaction on Monday, October 20th. The shares were sold at an average price of $22.08, for a total value of $276,000.00. Following the completion of the transaction, the insider directly owned 915,188 shares in the company, valued at approximately $20,207,351.04. This represents a 1.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Anish Patel sold 6,667 shares of the company's stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $20.10, for a total transaction of $134,006.70. Following the completion of the transaction, the chief operating officer owned 276,641 shares of the company's stock, valued at $5,560,484.10. This trade represents a 2.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 103,234 shares of company stock valued at $2,093,844. 25.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ELVN. Bank of New York Mellon Corp raised its holdings in Enliven Therapeutics by 4.5% in the 1st quarter. Bank of New York Mellon Corp now owns 93,567 shares of the company's stock worth $1,841,000 after purchasing an additional 3,992 shares in the last quarter. XTX Topco Ltd bought a new position in Enliven Therapeutics in the 1st quarter worth $430,000. BIT Capital GmbH bought a new position in Enliven Therapeutics in the 1st quarter worth $382,000. Invesco Ltd. raised its holdings in Enliven Therapeutics by 39.6% in the 1st quarter. Invesco Ltd. now owns 21,044 shares of the company's stock worth $414,000 after purchasing an additional 5,972 shares in the last quarter. Finally, Nuveen LLC bought a new position in Enliven Therapeutics in the 1st quarter worth $2,049,000. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.